Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

Darrell White; Adetola Kassim; Birbal Bhaskar; Jing Yi; Karen Wamstad; Virginia E. Paton

doi:10.1002/cncr.27745

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

Darrell White, Adetola Kassim, Birbal Bhaskar, Jing Yi, Karen Wamstad, Virginia E. Paton

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	339-347
Number of pages	9
Journal	Cancer
Volume	119
Issue number	2
DOIs	https://doi.org/10.1002/cncr.27745
Publication status	Published - Jan 15 2013
Externally published	Yes

ASJC Scopus Subject Areas

Oncology
Cancer Research

Keywords

bevacizumab
bortezomib
multiple myeloma
progression-free survival
safety
treatment outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cncr.27745

Cite this

@article{a500478a933046ee826a5efd2b058989,

title = "Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma",

keywords = "bevacizumab, bortezomib, multiple myeloma, progression-free survival, safety, treatment outcome",

author = "Darrell White and Adetola Kassim and Birbal Bhaskar and Jing Yi and Karen Wamstad and Paton, {Virginia E.}",

year = "2013",

month = jan,

day = "15",

doi = "10.1002/cncr.27745",

language = "English",

volume = "119",

pages = "339--347",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

AU - White, Darrell

AU - Kassim, Adetola

AU - Bhaskar, Birbal

AU - Yi, Jing

AU - Wamstad, Karen

AU - Paton, Virginia E.

PY - 2013/1/15

Y1 - 2013/1/15

KW - bevacizumab

KW - bortezomib

KW - multiple myeloma

KW - progression-free survival

KW - safety

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84872068442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872068442&partnerID=8YFLogxK

U2 - 10.1002/cncr.27745

DO - 10.1002/cncr.27745

M3 - Article

C2 - 22811009

AN - SCOPUS:84872068442

SN - 0008-543X

VL - 119

SP - 339

EP - 347

JO - Cancer

JF - Cancer

IS - 2

ER -

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this